Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. [electronic resource]
Producer: 20150428Description: 5405-14 p. digitalISSN:- 1476-5594
- Animals
- Antibodies, Monoclonal -- pharmacology
- Carcinoma, Pancreatic Ductal -- metabolism
- Cell Movement -- genetics
- Cell Survival -- genetics
- Female
- Humans
- Immunotherapy -- methods
- Intercellular Signaling Peptides and Proteins -- metabolism
- Mice, Nude
- Molecular Targeted Therapy
- Pancreatic Neoplasms -- immunology
- Phosphorylation -- drug effects
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins p21(ras)
- Receptor Protein-Tyrosine Kinases -- genetics
- Xenograft Model Antitumor Assays
- ras Proteins -- genetics
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.